Skip to main content
Premium Trial:

Request an Annual Quote

Onyx Raises $10 Million, Extends Warner-Lambert Deal for Three Years


RICHMOND, Calif.--Onyx Pharmaceuticals, a genetically oriented drug development company, has sold over 1.4 million shares to two institutional investors at $7.13 per share, raising $10 million. The company said it will use the money to fund ongoing research and development efforts oriented toward cancer treatments.

The lead investor is London-based International Biotechnology Trust, which is managed by Rothschild Bioscience. Another manager is Lombard Odier. As part of the deal Nicole Vitullo, senior vice-president of the Rothschild unit, will become a director of Onyx.

In other news, Onyx announced that the pharmaceutical company Warner Lambert has extended a three-year research agreement by another three years. The original partnership was scheduled to expire in May.

The extension means Onyx will receive $25 million in committed funding from Parke-Davis, Warner Lambert's research division, plus milestones prior to commercialization of any products. Onyx said it has already received $10.3 million in payments from the original agreement, and will receive another $6.2 million by May. In all, the six-year deal could bring in up to $50 million plus milestones, according to Onyx.

Filed under

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.